BIOFORCE NANOSCIENCES HOLDINGS, INC. ANNOUNCES ITS 1 FOR 5 REVERSE STOCK SPLIT, EFFECTIVE FEBRUARY 28, 2020

Virginia Beach, Virginia- Feb. 27, 2020-– Bioforce Nanosciences Holdings, Inc. (BFNH:OTC) (BFNHD:OTC) implemented a 1-for-5 reverse split of its common stock to be effective prior to the opening of the market tomorrow, Friday, February 28, 2020

The stock begin trading on a post-split basis under the symbol, BFNHD, for 20 business days, after which it will return to trading under the symbol, BFNH.

The majority stockholders approved BFNH’s reverse stock split, and on December 2, 2019, the record date of the corporate action, and the board of directors approved the implementation of the reverse stock split at the ratio of 1-for-5.

As a result of the split, every 5 (five) shares of issued and outstanding old common stock will be exchanged for 1 (one) share of new common stock under the new CUSIP number 09064C206. No fractional shares of common stock will be issued as a result of the reverse stock split. In lieu of receiving fractional shares, all such fractions shall be rounded up so that shareholders of record receive one whole share for each fractional share.

Each stockholder’s percentage ownership interest in BioForce Nanosciences Holdings, Inc., their proportional voting power, and the rights and privileges as the holders of the common stock remain unchanged and unaffected.

The reverse stock split did not change the total number of shares of common Stock  or preferred stock authorized for issuance by the Company; 900,000,000 total number of common shares,  par value $0.001 per share, and 100,000,000 shares of preferred stock, par value $0.001 per share, authorized.

Shareholders holding share certificates will receive information from BioForce’s transfer agent regarding the process for exchanging their shares of common stock. No service charge will be paid by existing shareholders for the exchange of the shares, and the Company will pay all expenses of the transfer and issuance of new shares.

The Board of Directors believes that the reverse stock split should encourage greater interest in the Company’s common stock by the investment community, and believes that the recapitalization of its market price of the Company’s common stock might become acceptable to institutional investors, professional investors and other members of the investing public.

For further information about this release, contact Richard Kaiser, 757-306-6090, info@bioforceeclipse, yes@yesinternational, www.yesinternational.com and www.bioforceeclipse.com.


Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competitions.

ELEMENT GLOBAL, INC. (ELGL) NAMES INDUSTRY VETERAN MR. GARY L. LEWIS AS BOARD OF DIRECTOR AND CEO OF WHOLLY-OWNED SUBSIDIARY, ELEMENT GLOBAL MINING, INC.

Los Angeles, CA- August 20, 2019- Element Global, Inc. (OTCMARKETS: ELGL) announces that Mr. Gary L. Lewis joined the Company as a Director and became the Chief Executive Officer of Element Global Mining, Inc., a wholly-owned Subsidiary.

Mr. Lewis holds a Bachelor of Commerce and Masters of Business & Technology (MBT) from the University of New South Wales, Sydney, Australia. With over 30-years experience in international capital markets and business and strategy development, he has founded, financed and/or operated resource projects or assets valued at more than US$400m, including the acquisition and ultimate sell-down or listing of high-value, multi-commodity resource projects in Australia, Asia and the Americas. Mr. Lewis has held numerous senior executive board positions in companies listed on Toronto Stock Exchange (TSX), Australian Securities Exchange (ASX) and the London Stock Exchange (AIM).

Mr. Lewis was most recently the founder and Managing Director of Battery Mineral Resource Limited (BMR), a battery mineral explorer and developer which focused on cobalt, lithium and graphite in Canada, USA and South Korea. Since July 2016, he worked to acquire over 9,000 mineral tenements in Canada and the USA, creating the largest landholding of high-grade cobalt in North America. In addition to cobalt, he created North America’s largest lithium brine exploration project in the western USA and acquired South Korea’s largest and only NI 43-101 compliant graphite resource.

Prior to BMR, Mr. Lewis founded Robust Resources Limited (Robust), an ASX-listed mineral explorer and developer that focused on precious and base metals and manganese in Australia, Indonesia, and the Philippines. As Managing Director, he propelled Robust to become the second-best performing company on the ASX in 2009 and 2010, before privatizing the Company in 2014.

As a founder and Executive Chairman of Tengri Resources, he acquired multi-million-ounce precious metal and multi-billion pound copper holdings throughout Central Asia before listing the Company on AIM (UK).

Merle Ferguson, Chairman, ELGL, states, “We welcome Mr. Lewis to the ELGL team to support our goal of commercializing our mining assets. He is a highly accomplished in the development and commercialization of mining assets around the world. His experience and commitment to delivering results will be of tremendous assistance in supporting the Company’s expected successes.”

For further information about this release, you can contact Investor Relations at YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.yesinternational.com and www.elementglobal.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

ELEMENT GLOBAL, INC’s (ELGL) SUBSIDIARY CLARINOVA TO START MINING FEASIBILITY STUDY

Los Angeles, CA- August 15, 2019- Clarinova Limited, a wholly-owned subsidiary of Element Global Inc. (ELGL: OTCMARKETS), announces the beginning to undertake a NI 43-101  geological feasibility survey of its audited mining tailing assets.

The plan calls for Clarinova Limited to utilize the resources of Element Global Mining Enterprises, Inc., the wholly-owned mining subsidiary of Element Global, Inc. to undertake the technical survey and testing starting this September 2019.

“NI 43-101 Standards” is a Canadian National Instrument for the “Standards of Disclosures for Mineral Projects.” The reports defined the mineral resources and mineral reserves on mining projects and properties. Each of these terms is divided into subcategories based on the quality and amount of work done to verify the amounts of minerals available and the economic viability of extracting them. A mineral resource is defined as a concentration or occurrence of minerals in such form and quantity and of such grade or quality that it has reasonable prospects for economic extraction. The three different types of mineral resources are metallic, nonmetallic and fossil fuels.

Merle Ferguson, Chairman, states, “Getting our project to a 43-101 standard provides the Company with a bankable feasibility of the economic values of the mineral tailings held in Clarinova Ltd.”

Even though ELGL is a US entity which trades in the US, it is  producing a bankable feasibility study to the qualification and quantification of the internationally recognized Canadian NI 43-101 standards, which remains an essential validation of the content and values of both precious and base metals in the mineralized tailings. Moreover, if the Company should decide to dual-list its equity on a Canadian stock exchange or perhaps the London Stock Exchange, the feasibility would facilitate such a listing.

For further information about this release, you can contact Investor Relations at YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.yesinternational.com and www.elementglobal.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

PREDICTIVE TECHNOLOGY GROUP ANNOUNCES THE PRESENTATION OF NEW DATA DEMONSTRATING THE GENETIC BASIS OF ENDOMETRIOSIS AT ESHRE

SALT LAKE CITY (June 25, 2019) – Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that data from a study of the genes underlying endometriosis may lead to new pathophysiology insights, improved diagnostics and novel treatment approaches. The study data was discussed in an oral presentation by Kenneth Ward, M.D. at the 2019 European Society of Human Reproduction and Embryology (ESHRE) annual meeting in Vienna, Austria. 

The abstract of the presentation “Excess germline mutations in four genes in unrelated women with surgical endometriosis” is available at https://www.eshre.eu/ESHRE2019/Programme/Searchable#!abstractdetails/0000581010.  

“Predictive Laboratories is committed to comprehensive disease management and advancing research into the genetic cause of endometriosis to improve the diagnosis and management of patients suffering from the disease,” said Bradley Robinson, CEO of Predictive Technology Group. “Our investment in technology has led to the identification of additional germline DNA changes associated with endometriosis.”

The study was conducted to identify genes in patients with endometriosis versus the general population. Whole exome sequencing was used to identify four genes (ZNF586, LUZP4, POP4 and UNC5CL) with significant gene burden in over 2,500 women with endometriosis, which was significant versus the general population (p<5 x 10-8). The four newly discovered mutated genes are all involved in the regulation of gene expression. Importantly, it was found that one in four women with endometriosis carry a mutation in one of these genes, while the population frequency is only 8%.

“Our research may lead to a better understanding of the pathophysiology of endometriosis,” said Dr. Ward, CEO of Juneau Biosciences, Laboratory Director of Predictive Laboratories and a member of the Predictive Technology Group Scientific Advisory Board. “Given the pace of innovation for targeted therapy, we are thrilled to present clinically relevant insights that may result in improved treatment of infertility as a result of endometriosis.”

About Endometriosis

Endometriosis occurs when the endometrial tissue that lines the uterus grows outside of the uterus and onto other areas of the body. Symptoms include pelvic pain, heavy periods, pain during sexual intercourse or bowel movements and infertility. Endometriosis affects 1 in 10 women worldwide in the reproductive age group. This prevalence increases to 1 in 3 women with infertility and 1 in 2 women with a normal cycle whose partner has normal sperm.

About ESHRE

The European Society of Human Reproduction and Embryology (ESHRE) is an international non-profit organization of about 8,000 members, whose main objective is to promote the study of human reproduction. ESHRE organizes the world’s major event in reproduction each year, publishes leading journals and guidelines, organizes lifelong learning programs and certification schemes, and monitors European IVF data.

Selection of the abstract for publication in the press program does not imply endorsement by ESHRE of the products and/or services that Predictive Laboratories offers.

About Predictive Laboratories, Inc.

Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, called ARTGuide™, to selected Beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns, in 2018. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.comPredrx.comPredictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

ELEMENT GLOBAL, INC. (ELGL) TO MOVE CORPORATE OFFICES TO SOUTHERN CALIFORNIA

ELEMENT GLOBAL, INC. (ELGL) TO MOVE CORPORATE OFFICES TO SOUTHERN CALIFORNIA

Virginia Beach, VA- June 6, 2019- Element Global, Inc. (ELGL: OTC) announces that it will move its corporate office from Virginia Beach, Virginia to Southern California, USA.

Management believes that its office move will better serve the interest of the Company’s operations with the intended move to California.

After reviewing several locations in Southern California, management expects to make a final decision with an announcement to follow on the new address.

As more information becomes available, the Company plans to update accordingly.

For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, at 757-306-6090, yes@yesinternational.com and www.yesinternational.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Predictive Technology Group Submits Application to List on NASDAQ

SALT LAKE CITY, May 02, 2019) — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces submission of its application to list its common stock on NASDAQ.

 The Company’s management has completed the application and submitted the request to list Predictive on The NASDAQ Exchange. The listing of the Company’s common shares remains subject to the approval of NASDAQ and the satisfaction of all applicable listing standards.

 As more information becomes available, Predictive will update the process on its intended up-listing accordingly.

 About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.

 Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Doyen Elements International Rebrands to Covalent Collective and Appoints Bill Gregorak as Chief Executive Officer

Colorado Springs, CO, Jan. 08, 2019– Doyen Elements International, Inc., a burgeoning network of vertically integrated cannabis businesses, announces its rebranding and renaming itself to Covalent Collective, Inc. (“Covalent Collective” or the “Company”). In addition, the Company announced Bill Gregorak as Chief Executive Officer, effective immediately. Prior to being named CEO, Mr. Gregorak served as Chief Financial Officer of Covalent Collective since February 2018. Mr. Gregorak takes over as CEO from Geoffrey Thompson, a co-founder of Covalent Collective, who will continue as leader of merger and acquisitions.

“The cannabis industry is evolving even more rapidly than any of the experts expected, and Covalent Collective’s value proposition differentiates us in a crowded marketplace.  Over the coming weeks, months and years, the vision we have will yield tremendous shareholder value, and position us for exponential growth,” said Mr. Thompson. “We are confident that the rebrand and name change to Covalent Collective effectively aligns with our core mission of building out a vertically integrated network of unique cannabis enterprises. It also allows us to capitalize on this rapidly expanding market by providing a means to greatly enhance and accelerate our partners’ growth potential. As we continue to grow Covalent Collective, we will focus our efforts on both organic growth and strategic acquisitions.”

In his role, Mr. Gregorak will direct all business units and strategy for Covalent Collective. Mr. Gregorak will also oversee the execution of the Company’s rebranding and acquisition strategy of plant-touching enterprises that grow, process and sell cannabis products.

“As a seasoned executive, Bill Gregorak brings to bear more than two decades of public company experience. Coupled with his broad background in managing relationships with customers, partners and investors, Bill has the right combination of skills and experience to lead our company and senior management team,” added, Mr. Thompson. “Throughout the search process, Bill’s unique skill set stood out as the best candidate for the CEO position and we are thrilled to have him lead us into our next level of growth and expansion.”

Prior to joining Covalent Collective, Mr. Gregorak served as CFO for publicly traded companies on both the NASDAQ and the OTC markets including Two Rivers Water and Farming, a company that builds and leases greenhouses optimized for marijuana cultivation and also specializes in the development of water resources for municipal, commercial and agricultural usage in Southwest Colorado.  Mr. Gregorak also spent nearly 20 years with tech giant Hewlett-Packard in various financial and operational capacities.

“Before taking Covalent Collective to the next level, we needed to develop a more sophisticated brand, one that better reflects our mission,” said Mr. Gregorak. “As we take this next step, our goal is to provide tremendous value to our partners, investors and potential shareholders. In order to achieve this, we are confident that a diversified, innovative collective of vertically integrated cannabis enterprises will allow us to optimize efficiency across the entire cannabis ecosystem.”

About Covalent Collective:

Covalent Collective, Inc. is a British Columbia, Canada company founded in 2014 and headquartered in Colorado Springs, CO. The Company is building a diverse network of vertically integrated cannabis-centric enterprises that span the entirety of the legal cannabis and hemp industries. With a vision to build the largest grow capacity in the U.S., Covalent Collective’s mission is to create stronger bonds throughout the greater cannabis community through the execution of a strategic acquisition and joint venture strategy that is strategically positioned to support eventual federal legalization in the United States. For more information, please visit https://covalentcannabis.com.

Media Contacts:
Nick Opich / Cynthia Salarizadeh
KCSA Strategic Communications
(212) 896-1206 / (856) 425-6160

Investor  Relations:

Rich Kaiser

YES INTERNATIONAL

757-306-6090

ir@covalentcollective.co

yes@yesinternational.com

 

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward- looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, including statements with respect to the Company’s rebranding and acquisition strategies. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance or achievements could differ materially from those expressed in, or implied by, any forward-looking statements in this press release, and readers should not place undue reliance on any such forward-looking statements since they are not guarantees of future results. The Company does not undertake and specifically declines any obligation to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.

DOYEN ELEMENTS: MEDICAL CANNABIS HOLDING COMPANY UNDER CONTRACT TO ACQUIRE 16 COMPANIES IN COLORADO

Advantameds Solutions USA Fund 1, Inc. changes its name to Doyen Elements better reflecting its focus as a Full-Service Real Estate Investor and Cannabis Consultancy Firm through the Acquisition of 16 Cannabis Portfolio Companies 

CHICAGO, IL-June 14, 2017-  Doyen Elements, previously Advantameds Solutions USA Fund 1, Inc., announced today that it is under contract to acquire 16 ancillary cannabis (non-plant touching) operating entities. Doyen Elements has emerged as a full-service consultancy company for the Cannabis industry, further establishing itself as an industry changing investment vehicle.  Doyen Elements provides canna-businesses with real estate investments, full-service management, financial, operational, technology and automation services.  The management team of the 16 portfolio companies that will comprise Doyen Elements brings expertise, including vertical market solutions, cultivation facilities, and other support businesses.

The company has created a total business ecosystem for the Cannabis industry by establishing the 5 Pillars that make up Doyen Elements and the services offered:

  • Real Estate Services – Doyen continues to acquire real estate entities and develop assets. These assets will be utilized by license holders that are legal in their respective space and to easily scale cultivation efforts for those legally selling cannabis. Doyen Elements is expecting to have 1 million square feet in their portfolio by 2021. Additionally, the company provides a means for wholesale distribution by accelerating and increasing the growth and yield of product for distribution.
  • Consulting and Management Services – With over 9 years of full-scale operational experience in the cannabis industry, Doyen Elements offers industry-leading consulting and management services. Expertise ranges from immediate start-up business activation and licensing, growth structure, tenant improvements, general management, security, transportation, compliance and legal services. Doyen Elements not only provides a detailed roadmap for existing companies seeking to address these issues but have teams in place that can roll up their sleeves to provide Clients with tactical action-oriented assistance in any start-up.
  • Research and Development – When the acquisitions are complete, Doyen’s exclusive patent licensing agreement for the use of the Transdermal Patch will provide national distribution opportunities to the cannabis industry. The company intends to use of this to benefit Doyen business partners, who will leverage this patent when seeking to provide a solution for those suffering from ailments or chronic illnesses that may benefit from the use of transdermal patches.
  • Industrial Equipment – Utilizing the chain of successful stores known as Hydroponics Depot, Doyen intends to sell hydroponic equipment, nutrients, additives etc. required to operate clean, high-quality cultivation facilities.
  • Working Capital and Green Construction Operations – Doyen Elements will utilize its construction expertise and provide LEED Certifiable solutions in the building of cultivation facilities and retail structures. Syntheto Foam System, which has proven to be mold and pest resistant and will more than double the R-Factor of the entire structure.   The Company will also provide its clients with innovative green construction solutions that not only help decrease operational costs but will also provide maximum growing and cultivation ease.

“We are delighted to announce the formation of Doyen Elements,” says Chief Operating Officer Cindy Boerum.  “Doyen will bring stature and speed to the entire burgeoning cannabis ecosystem. By creating a consultancy that provides category-defining business acumen and direct access to an experienced management team with hands-on operational experience, the Company will provide nascent and middle market cannabis ventures with the cross-functional know-how needed to quickly accelerate their canna-businesses. “

The addition of the vertices will not only allow the company to offer the best in class services to ‘Canna-businesses,’ but offer investors a vehicle to invest in the top management teams within the growing Cannabis space, and provide a diverse portfolio of industry-leading Cannabis support businesses for investors through full-service management, financial, operational, and execution services.

For additional information about Doyen Elements, Inc. direct investment offering, contact Rich Kaiser, Investor Relations YES INTERNATIONAL 757-306-6090 yes@yesinternational.com

Forward-Looking Statements:

This communication shall not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state in which such solicitation or sale would be unlawful prior to registration or qualification of these securities under the laws of any such state.

This Press Release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.  These “forward-looking statements” that address activities, events or developments that Doyen Elements, Inc. expects, anticipates, or estimates may occur in the future.  Generally forward-looking statements by words such as “may,” “will,” “would,” “could,” “continue,” “potential,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend” and other similar expressions. There are a numerous risks and uncertainties, both known and unknown, that could cause actual results to differ materially from the results implied by the forward-looking statements, which may include but are not limited to, business risks, general industry conditions and competition, general economic factors, governmental actions, legislative conditions, the impact of cannabis industry regulation, legislation in the United States and internationally and technological advances.  Doyen Elements undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Predictive Technology Group, Inc. (PRED) Announces US Patent for Method for Performing an Advanced Reproductive Therapy Supporting Licensed Technology from Juneau Biosciences

Acquisition Strengthens Commercialization Strategy of Company’s Gene Therapy Products

Salt Lake City, UT — (January 12, 2017) – Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announces the issuance of US patent 9,434,991 direct to a method for performing an Advanced Reproductive Therapy (“ART”).

The Centers for Disease Control and Prevention (”CDC”) estimates 208,604 ART cycles were performed in 2014 resulting in 70,354 live births in the United States in 2014. Mike Schramm, PRED’s Director of Intellectual Property, described the claims of 9,434,991 as covering any in vitro fertility treatment of an egg of a woman having any gynecological disorder associated biomarker.

“The issuance of this US patent significantly strengthens PRED’s Intellectual Property position and mission of assisting parents in delivering the healthiest babies possible,” said Bradley Robinson, President and Chief Executive Officer of PRED. “The rights to this technology are seen as a synergistic companion to our medicinal therapeutic products.”

According to Technavio’s latest report, the global fertility services market is expected to exceed USD 21 billion by 2020, growing at a CAGR of almost 9% during the forecast period.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL at 757-306-6090, yes@yesinternational.com, www.predictivetechnologygroup.com, www.predrx.com, and www.yesinternational.com.

 Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

 

Predictive Technology Group, Inc. (PRED) Announces Acquisition of US Patent Application for Method for Treating Patients with Stem Cells “Cleaned” via CRISPR

Acquisition Strengthens Commercialization Strategy of Company’s Gene Therapy Products

Salt Lake City, UT — January 10, 2017 – Predictive Technology Group, Inc. (OTCPINK: PRED), a life sciences technology holding company, announced the acquisition of US patent application 62/295,042 direct to the practice of “cleaning” stem cells of a predetermined disease-associated marker via theClustered Regularly Interspaced Short Palindromic Repeats CRISPR” process and administering the stem cells to the patient.

“Clustered Regularly Interspaced Short Palindromic Repeats” (CRISPR) technology offers several advantages over previous forms of gene-editing. The human cell’s genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. Unlike other current practices which involve the introduction of foreign DNA.

“The claims are drawn to the ’cleaning‘ of any stem cell having a predetermined disease associated biomarker,” said Mike Schramm, PRED’s Director of Intellectual Property.  “Because the patent application is for both autologous (withdrawn from and reintroduced to the same patient) and homologous (derived from another source), we see very broad use of the application.”

These rights enable PRED to both diagnose a patient for a genetic disease based on a specific biomarker and subsequently treating the patient with their own stem cells having the diagnosed biomarker eliminated via the CRISPR method.

“This is a significant opportunity for our company to obtain the rights to this invention,” said Bradley Robinson, President and Chief Executive Officer of PRED. “The technology is a strong bridge between our Molecular Diagnostic and Regenerative Medicine product portfolios.”

The global genome editing market is expected to reach USD $5.54 Billion by 2021 from USD $2.84 Billion in 2016, growing at a CAGR of 14.3%. (Source: Market and Market 2016 Genome Editing and Genome Engineering Report)

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com and www.predictivetechnologygroup.com. 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.